Divi's Laboratories share news and announcements
NSE: DIVISLABBSE: 532488Pharmaceuticals & BiotechnologyLarge Cap
Last close ₹8,950.00down ₹212.00 (2.31%)BSE ₹8,984.00
Share price at the NSE close on 23 Oct 2026. Previous close ₹9,162.00.
52-week range of traded prices to 23 Oct 2026
₹5,647.50Low, 2 Apr 2026₹9,740.00High, 24 Sep 2026
- Next results date: the board meets on 7 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹2,37,594 Cr50th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 1 Aug 2026
- 81.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 27 May 2026
- 14.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.34%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 1 Aug 2026
- 18.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 1 Aug 2026
- 20.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 27 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 6,20,26160.6% delivered
Divi's Laboratories board and management
19 filed, newest first.
Sep 2025
5 Sep · Management
Apr 2025
Feb 2025
3 Feb · Management
3 Feb · Management
Jun 2024
22 Jun · Management
22 Jun · Management
May 2024
25 May · Management
Feb 2024
10 Feb · Management
Aug 2023
Aug 2019
May 2019
Mar 2019
May 2018
26 May · Management
Jul 2017
Jun 2014
23 Jun · Management
May 2013
20 May · Management
Prof. C. Ayyanna, Independent Director of the Company has resigned from the Board due to personal reasons and other pre-occupations. The Board has accepted his resignation and appreciated his contribution to the Company.
Nov 2012
5 Nov · Management
Board of Directors of the Company at its meeting held on November 03, 2012, has appointed Sri. Ranga Rao Ravipati as Additional Director (Independent and Non-Executive) on the Board of the Company w.e.f. November 03, 2012. Further, the Company has informed the Exchange that, Sri. G. Venkata Rao, Independent Director of the Company has resigned from the Board due to personal reasons and other pre-occupations. The Board has accepted his resignation and appreciated his contribution to the Company.
Jan 2012
30 Jan · Management
Dr. P. Gundu Rao, Non-Executive Director of the Company has resigned from the Board as he relocated to the USA to spend time with his family. The Board has accepted his resignation and appreciated his constribution to the Company.